Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells

Cancer Immunology, Immunotherapy

Volumn 67, Issue 9, 2018, Pages 1407-1416

  Mishra, Hemant K ^a   Pore, Nabendu ^b   Michelotti, Emil F ^b,c   Walcheck, Bruce ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MedImmune LLC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antibody; Cancer; Cytokine; Cytotoxicity; Immunotherapy; NK cell

Indexed keywords

3G 8; BMS 566394; CD16A ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANZYME A; GRANZYME B; LYMPHOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MEDI 3622; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG; ADAM17 PROTEIN, HUMAN; ADAM17 PROTEIN, MOUSE; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; IFNG PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NK-92 CELL LINE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAJI CELL LINE; SK-OV-3 CELL LINE; TUMOR CELL; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; DRUG EFFECT; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ADAM17 PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LEUKOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IGG;

EID: 85049558882     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-018-2193-1     Document Type: Article

References (49)

1. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47. 10.1038/nri2206
2. Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368. 10.3389/fimmu.2015.00368
3. Harrison D, Phillips JH, Lanier LL (1991) Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated Fc gamma RIII (CD16-II). J Immunol 147:3459–3465
4. Wang Y, Wu J, Newton R, Bahaie NS, Long C, Walcheck B (2013) ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils. Biochim Biophys Acta 1833:680–685. 10.1016/j.bbamcr.2012.11.027
5. Romee R, Foley B, Lenvik T et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121:3599–608. 10.1182/blood-2012-04-425397
6. Peruzzi G, Femnou L, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE (2013) Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol 191:1883–1894. 10.4049/jimmunol.1300313
7. Lajoie L, Congy-Jolivet N, Bolzec A et al (2014) ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol 192:741–751. 10.4049/jimmunol.1301024
8. Jing Y, Ni Z, Wu J, Higgins L, Markowski TW, Kaufman DS, Walcheck B (2015) Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS One 10:e0121788. 10.1371/journal.pone.0121788
9. Weiner GJ (2015) Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 15:361–370. 10.1038/nrc3930
10. Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76. 10.3389/fimmu.2013.00076
11. Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S (2013) Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther 13:739–764. 10.1517/14712598.2013.767328
12. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278–287. 10.1038/nrc3236
13. Natsume A, Niwa R, Satoh M (2009) Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Devel Ther 3:7–16
14. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2:161–173
15. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, Button A, Link BK, Weiner GJ (2011) Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 118:3347–3349. 10.1182/blood-2011-05-351411
16. Cox MC, Battella S, La Scaleia R et al (2015) Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology 4:e990773. 10.4161/2162402X.2014.990773
17. Felices M, Chu S, Kodal B et al (2017) IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol 145:453–461. 10.1016/j.ygyno.2017.02.028
18. Granzin M, Soltenborn S, Muller S, Kollet J, Berg M, Cerwenka A, Childs RW, Huppert V (2015) Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 17:621–632. 10.1016/j.jcyt.2015.03.611
19. Duffy MJ, Mullooly M, O’Donovan N, Sukor S, Crown J, Pierce A, McGowan PM (2011) The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin. Proteomics 8:9. 10.1186/1559-0275-8-9
20. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280:19543–19550. 10.1074/jbc.M410943200
21. Shen H, Li L, Zhou S et al (2016) The role of ADAM17 in tumorigenesis and progression of breast cancer. Tumour Biol. 10.1007/s13277-016-5418-y
22. Mustafi R, Dougherty U, Mustafi D et al (2017) ADAM17 is a tumor promoter and therapeutic target in western diet-associated colon cancer. Clin Cancer Res 23:549–561. 10.1158/1078-0432.CCR-15-3140
23. Buchanan PC, Boylan KLM, Walcheck B, Heinze R, Geller MA, Argenta PA, Skubitz APN (2017) Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem 292:6339–6351. 10.1074/jbc.M116.746859
24. Tape CJ, Willems SH, Dombernowsky SL, Stanley PL, Fogarasi M, Ouwehand W, McCafferty J, Murphy G (2011) Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci USA 108:5578–5583. 10.1073/pnas.1017067108
25. Richards FM, Tape CJ, Jodrell DI, Murphy G (2012) Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 7:e40597. 10.1371/journal.pone.0040597
26. Kwok HF, Botkjaer KA, Tape CJ, Huang Y, McCafferty J, Murphy G (2014) Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng Des Sel 27:179–190. 10.1093/protein/gzu010
27. Caiazza F, McGowan PM, Mullooly M et al (2015) Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer 112:1895–1903. 10.1038/bjc.2015.163
28. Rios-Doria J, Sabol D, Chesebrough J et al (2015) A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways. Mol Cancer Ther 14:1637–1649. 10.1158/1535-7163.MCT-14-1040
29. Dosch J, Ziemke E, Wan S et al (2017) Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency. Oncotarget 8:65090–65099. 10.18632/oncotarget.17780
30. Peng L, Cook K, Xu L, Cheng L, Damschroder M, Gao C, Wu H, Dall’Acqua WF (2016) Molecular basis for the mechanism of action of an anti-TACE antibody. mAbs 8:1598–1605. 10.1080/19420862.2016.1226716
31. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109
32. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75:163–189. 10.1189/jlb.0603252
33. Wang R, Jaw JJ, Stutzman NC, Zou Z, Sun PD (2012) Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol 91:299–309. 10.1189/jlb.0611308
34. Kammertoens T, Friese C, Arina A et al (2017) Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression. Nature 545:98–102. 10.1038/nature22311
35. Mishra HK, Long C, Bahaie NS, Walcheck B (2015) Regulation of CXCR2 expression and function by a disintegrin and metalloprotease-17 (ADAM17). J Leukoc Biol 97:447–454. 10.1189/jlb.3HI0714-340R
36. Mishra HK, Johnson TJ, Seelig DM, Walcheck B (2016) Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis. J Leukoc Biol 100:999–1004. 10.1189/jlb.3VMAB1115-496RR
37. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM (2008) Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 180:6392–6401
38. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510. 10.1038/ni1582
39. Frey M, Packianathan NB, Fehniger TA, Ross ME, Wang WC, Stewart CC, Caligiuri MA, Evans SS (1998) Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 161:400–408
40. De Maria A, Bozzano F, Cantoni C, Moretta L (2011) Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 108:728–732. 10.1073/pnas.1012356108
41. Larsen SK, Gao Y, Basse PH (2014) NK cells in the tumor microenvironment. Crit Rev Oncog 19:91–105
42. Perussia B, Trinchieri G (1984) Antibody 3G8, specific for the human neutrophil Fc receptor, reacts with natural killer cells. J Immunol 132:1410–1415
43. Mishra HK, Ma J, Walcheck B (2017) Ectodomain shedding by ADAM17: its role in neutrophil recruitment and the impairment of this process during sepsis. Front Cell Infect Microbiol 7:138. 10.3389/fcimb.2017.00138
44. Choi PJ, Mitchison TJ (2013) Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proc Natl Acad Sci USA 110:6488–6493. 10.1073/pnas.1221312110
45. Vanherberghen B, Olofsson PE, Forslund E et al (2013) Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood 121:1326–1334. 10.1182/blood-2012-06-439851
46. Guldevall K, Brandt L, Forslund E et al (2016) Microchip screening platform for single cell assessment of NK cell cytotoxicity. Front Immunol 7:119. 10.3389/fimmu.2016.00119
47. Paul S, Lal G (2017) The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol 8:1124. 10.3389/fimmu.2017.01124
48. Kanzaki H, Shinohara F, Suzuki M et al (2016) A-disintegrin and metalloproteinase (ADAM) 17 enzymatically degrades interferon-gamma. Sci Rep 6:32259. 10.1038/srep32259
49. Battella S, Cox MC, Santoni A, Palmieri G (2016) Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J Leukoc Biol 99:87–96. 10.1189/jlb.5VMR0415-141R